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564 Abstracts February 2014Board approval was obtained, patients were retrospectively and then pro-
spectively identiﬁed and followed up for a 2-year period.
Results: Sixty-three AAAVgs were reviewed. Patient were an average
age of 55 years (range, 23-85 years), and 93% had documented prior access.
Thirty-eight patients required graft interventions in the follow-up period.
Twenty-one balloon angioplasties were performed for outﬂow venous ste-
nosis. Fourteen grafts thrombosed at an average of 461 days after implant.
Seven patients had bacteremia resulting in four graft removals (6%) as the
infective source. Two wound complications (one hematoma, one superﬁcial
wound dehiscence) occurred, but the graft was preserved. Notably, no pa-
tient required treatment for steal. The average primary patency rate was 85%
at 30 days, 51% at 6 months, and 33% at 1 year. Primary assisted patency was
90% at 6 months, 79% at 1 year, and 37% at 2 years. Secondary patency was
92% at 6 months and 58% at 1 year. Twenty-one patients required a new
access at an average of 477 days after the initial placement. Since receiving
their grafts, 25 of the 63 patients have died, and one patient received a
transplant.
Conclusions: AAAVgs are appropriate for patients who have few up-
per extremity access options. The patency rates for this “bailout” procedure
are at least equivalent to other upper extremity AV grafts. The lack of symp-
tomatic steal is an important beneﬁt. The infection rate is lower than in
femoral grafts, and correspondingly, AAAVgs can even be considered for
primary use in patients that have disadvantaged upper extremity vasculature
or who are at increased risk of steal syndrome.
Patient Compliance Limits the Efforts of Quality Improvement
Initiatives on Arteriovenous Fistula Maturation
Susanna K. Lynch, BS, Sadaf S. Ahanchi, MD, David J. Dexter, MD, Marc
H. Glickman, MD, Jean M. Panneton, MD. Eastern Virginia Medical
School, Norfolk, Va
Objectives: Our institutional quality improvement (QI) initiative
monitors the schedule for arteriovenous ﬁstula (AVF) maturation with
follow-up #30 days after creation, ﬁstulogram #40 days if indicated, and
a second ofﬁce visit #8 weeks. Additionally, a patient liaison contacts pa-
tients and dialysis units in cases of delayed follow-up. The purpose of this
study is to determine the impact of the QI initiative on patient compliance
and overall time to AVF maturation.
Methods: We performed a retrospective review of patients undergo-
ing initial radiocephalic (RC), brachiocephalic (BC), and basilic vein trans-
position (BVT) creation before the QI initiative (pre-QI group: January to
April 2012) and during the QI period (QI group: January to April 2013).
Categoric data were compared using c2 analysis, and nominal data were
compared using the Student t-test.
Results: We reviewed 198 ﬁrst-time AVF creations in patients (57%
male) with a mean age of 61 years. Demographics and comorbidities be-
tween the pre-QI and QI groups were similar. During the pre-QI period,
110 initial AVFs were created: 28% RC, 44% BC, and 28% BVT, whereas
during the QI period, 88 initial AVFs were created: 27% RC, 51% BC,
and 22% BVT (c2 ¼ 0.487). Compliance with the 30-day postoperative
appointment increased signiﬁcantly after the QI initiative, from 48% in
the pre-QI group to 65% in the QI group (P ¼ .015). Yet, the QI initiative
did not maintain an impact on the subsequent follow-up checkpoints. No
statistical difference was identiﬁed for compliance with ﬁstulogram #40
days of access creation (pre-QI: 12% vs QI: 25%; P ¼ .093) and for compli-
ance with the 8-week postoperative appointment (pre-QI: 33% vs QI: 23%;
P ¼ .457). Both checkpoints demonstrated a very high noncompliance rate.
Accordingly, time to maturation was 88 days for both the pre-QI and QI
group, with a failure to mature rate of 22% for the pre-QI group and 21%
for the QI group.
Conclusions: The QI initiative signiﬁcantly increased the number of
patients complying with the ﬁrst 30-day follow-up appointment after access
creation. However, patient compliance with a timely ﬁstulogram and the
second follow-up appointment was very poor and not inﬂuenced by the
QI initiative, limiting the functional impact of the QI initiative on time to
AVF maturation.
Outcomes of Percutaneous Suture-Mediated Vessel Closure in Venous
Interventions
Allan W. Tulloch, MD, Sharon C. Kiang, MD, Daniel S. Levi, MD, Jamil
Aboulhosn, MD, Brian G. DeRubertis, MD. UCLA, Los Angeles, Calif
Objectives: The safety and efﬁcacy of vascular closure devices in the
arterial system has been well documented. However, there are no reports
describing the use of these devices in the venous system, despite the
increasing frequency of percutaneous venous interventions, often involving
large-bore sheaths in anticoagulated patients. This report describes our
experience using the Perclose ProGlide (Abbott Vascular Devices, Pleasan-
ton, Calif) suture-mediated device in venous closure.Methods: A retrospective review of all patients undergoing off-label
venous access closure with the Perclose was performed from 2008 to
2012. Seventy patients (50% male; mean age, 28 years) underwent 70
femoral venous access closures for sheaths ranging from 9F to 22F (mean,
18F). A single Perclose device was used postintervention for sheaths up to
12F, and two Perclose devices were used with the “Perclose” technique
for sheaths >12F. Indications for intervention included nonthrombotic
May-Thurner syndrome with leg swelling, May-Thurner syndrome with
deep vein thrombosis, and pulmonary insufﬁciency requiring a percutaneous
pulmonic valve. All patients underwent full anticoagulation intraprocedur-
ally (activated clotting time >250 seconds) and at the time of vessel access
closure. Mean follow-up was 13 months, and consisted of a physical exam-
ination (all patients) and venous duplex ultrasound imaging (20%). Main
outcome measures were deep venous thrombosis (DVT) and access site
hematoma.
Results: During longitudinal follow-up, there were no documented
cases of DVT or access site hematoma. Venous duplex ultrasound imaging
was performed between 1 and 56 months postprocedurally, with normal
ﬂow documented in all studied patients. Six patients (9%) had ipsilateral
leg swelling necessitating imaging that demonstrated no evidence of DVT
or venous stenosis. Two deaths occurred (one <30 days, one late) due to
heart failure in pulmonary insufﬁciency patients, but neither was procedur-
ally related.
Conclusions: The use of suture-mediated devices in the venous sys-
tem appears to be well tolerated, with no documented cases of DVT in
our series. The absence of any occurrences of hematoma in these patients,
despite large-bore sheath access and full anticoagulation, suggests a clinical
beneﬁt for use of suture-mediated closure devices. Prospective studies with
routine duplex imaging after Perclose use in the venous system will better
elucidate the long-term safety of this technique.
United States National Survey of Vascular Surgery Consent
Mark E. O’Donnell, MMedSc, MD, FRCS, Grant T. Fankhauser, MD,
William M. Stone, MD, Richard J. Fowl, MD, Carolyn Pence-Smith,
Samuel R. Money, MD. Mayo Clinic, Phoenix, Ariz
Objectives: Currently, there are no explicit guidelines for informed
consent for vascular surgical interventions. Unfortunately, there is evidence
to suggest that consent deﬁciencies occur. The objective of this survey was
to catalog current peer practice and collate consensus relating to vascular
surgery patient consent.
Methods: A prospective anonymous online survey was adminis-
tered using Survey Monkey to members of the Society for Clinical
Vascular Surgery in June 2013. After completion of provider demo-
graphic details, each member evaluated general and procedural-speciﬁc
complications for arterial and venous interventions that should be dis-
cussed with patients during the informed consent process. Greater
than 75% reporting for a speciﬁc complication was deemed the threshold
for consensus opinion.
Results: Of 1210 members, 179 (14.8%) completed the survey. The
majority of respondents were staff surgeons (85.5%), followed by vascular
fellows (11.2%). Both groups considered vascular fellows competent to
obtain consent. The majority of patients were consented primarily by the
staff surgeons (67.6%) #24 hours of surgery (43%). This was done in the
outpatient (67.4%) or preoperative holding areas (66%). A procedure-spe-
ciﬁc, preprinted consent form was used in 95% of patients, with additional
written documentation provided in 59.7%. General complications discussed
before arterial surgery included bleeding (94.9%), cardiac (94.9%), cerebro-
vascular (92.6%), wound infection (90.4%), respiratory (78.7%), and throm-
boembolic (76%) events. Although respondents provided consent consensus
for a number of core vascular procedures, in patients undergoing open
aortic surgery, 10.2%, 14.4%, and 13.6% reported no discussion of bleeding,
impotence, or lower limb ischemia, respectively. Endoleak (5.6%), follow-up
surveillance (14.0%), graft occlusion/lower limb ischemia (8.4%), and rein-
tervention possibilities (10.3%) were additionally not documented during
EVAR consent by survey respondents. Surprisingly, cranial nerve injury
and restenosis were not discussed by 6.5% and 18.7% of vascular surgeons
performing carotid endarterectomy. For patients undergoing limb bypass
procedures, graft occlusion, limb loss, edema, and procedural failure were
not discussed in 5% to 9.9% of cases. General complications described dur-
ing venous procedures included bruising (90%), bleeding (86%), thrombo-
embolic events (87%), and wound infections (81.8%). However, nerve
injury, failure to improve symptoms, scarring, and recurrence were omitted
from discussion by 17.7%, 11.5%, 22.2%, and 12.5%, of respondents. Only
37% and 5.8% of vascular centers provided informal and formal consent
training, respectively.
Conclusions: The informed consent process presently used by most
providers is nonstandardized and inadequate. Recognized complications
for procedures are frequently not discussed during the informed consent
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informed consent process should be pursued by consensus groups.
Impact of Early and Delayed Postoperative Myocardial Infarction on
Late Survival in Patients Undergoing Vascular Surgery
Virendra I. Patel, MD, MPH, Emel Ergul, MS, Robert T. Lancaster, MD,
MPH, Glenn M. LaMuraglia, MD, Christopher J. Kwolek, MD, Richard P.
Cambria, MD, Mark F. Conrad, MD, MSSc. Massachusetts General
Hospital, Boston, Mass
Objectives: Perioperative myocardial infarction (MI) has been shown
to increase early and late mortality after vascular surgical (VS) procedures.
We evaluated the frequency and timing of MI after VS and its impact on sur-
vival across a heterogeneous cohort of VS patients.
Methods: All patients undergoing a spectrum of VS (open aortic
resection, endovascular aneurysm repair/thoracic endovascular aortic repair,
carotid endarterectomy/carotid angioplasty and stenting, or lower extrem-
ity bypass) from July 2007 to May 2012 were included. MI was diagnosed
by electrocardiogram changes, elevated troponin, or diagnosis by a cardiol-
ogist. Patients were identiﬁed by Current Procedural Terminology code us-
ing an institutional patient data research registry consisting of
administrative/clinical data and stratiﬁed according to the temporal rela-
tionship of the MI to the indexed procedure (early: #30 days; intermediate:
1 month to 1 year; late: >1 year). Univariate and multivariate methods were
used to identify predictors of MI and its impact on survival.
Results: We identiﬁed 2984 patients who underwent VS during the
study interval. Early MI was observed in 110 (3.7%), intermediate MI in
66 (2.2%), and late MI in 136 (4.5%). Patient age per year (odds ratio
[OR], 1.02; 95% conﬁdence interval [CI], 1.0002-1.05; P¼ .03) and history
of coronary artery disease (CAD; OR, 4.6; 95% CI, 2.8-7.5; P < .01) inde-
pendently predicted risk of early MI. Intermediate MI was predicted by his-
tory of CAD (OR, 3.2; 95% CI, 1.9-5.3; P< .01) and diabetes (OR, 1.7; 95%
CI, 1.1-2.7; P ¼ .02). Procedure type was not predictive of perioperative or
delayed MI. Patients who had an MI within the ﬁrst year had a lower (log-
rank P < .001) survival at 1 year (77% 6 3% vs 92% 6 1%) and 5 years
(61% 6 5% vs 71% 6 2%; Fig). Risk-adjusted (age, gender, CAD, race, hy-
pertension) Cox regression modeling showed that early MI (HR, 1.5; 95%
CI, 1.01-2.2; P ¼ .04) and, more importantly, intermediate MI (HR, 2.2;
95% CI, 1.5-3.2; P< .01) independently predicted increase in late mortality,
whereas late MI had no impact (HR, 1.03; 95% CI, 0.7-1.6; P ¼ .9).
Conclusions: The incidence of MI within the ﬁrst year after major
vascular procedures remains low yet is predicted by a history of CAD and
diabetes. Readily identiﬁable high-risk patients should have focused inten-
sive medical therapy before and after VS.
Fig. Late survival in vascular surgery patients stratiﬁed by MI.
Outcomes of Reoperative Open or Endovascular Interventions to
Treat Patients With Failing Open Mesenteric Reconstructions for
Mesenteric Ischemia
Karina S. Kanamori, MD1, Gustavo S. Oderich, MD1, Javairiah
Fatima, MBBS2, Timur Sarac, MD2, Daniel Clair, MD2, Stephen
Cha, MS1, Audra A. Duncan, MD1, Manju Kalra, MBBS1, Mark
Fleming, MD1, Randall R. De Martino, MD1, Peter Gloviczki, MD1,
Thomas C. Bower, MD1. 1Mayo Clinic, Rochester, Minn; 2Cleveland
Clinic, Cleveland, OhioObjectives: Outcomes of reinterventions for failing open mesenteric
reconstructions (ORs) have not been described. Reoperative ORs
(R-ORs) can be challenging because of excessive scar and more advanced
mesenteric disease. The purpose of this study was to evaluate outcomes of
R-ORs and endovascular revascularizations (ERs) in patients with stenosis
or occlusion of ORs.
Methods: We reviewed a cohort of 593 patients treated for chronic
mesenteric ischemia (CMI) in two academic centers from 1991 to 2013.
Clinical data and outcomes of patients treated for failing ORs with R-ORs
or ERs were included in the analysis. Case-control propensity score match-
ing was used to analyze outcomes of R-ORs compared with patients who
underwent their ﬁrst-time ORs for CMI. End points were early and late
mortality, morbidity, patency rates, and freedom from symptom recurrence
and reintervention.
Results: There were 47 patients (5 male, 42 female; mean age, 58 6
13 years) treated by reinterventions for failing ORs. Clinical presentation
was CMI in 38 patients (81%) or acute mesenteric ischemia (AMI) in
nine (19%). Reinterventions included R-ORs in 28 patients (19 CMI and
9 AMI) and ERs in 19, all for CMI. Early mortality was 22% in patients
treated by R-ORs for AMI. There were no early deaths among patients
treated for CMI with R-OR or ER. Early morbidity was 78% for R-ORs
in patients treated for AMI. Morbidity was signiﬁcantly higher for R-ORs
than for ERs in patients with CMI (68% vs 16%; P < .001). Mean
follow-up was 50 6 60 months. Patient survival at 5 years was 60% 6 8%
for the entire cohort. Primary and secondary patency at 1 year was 61% 6
10% and 92% 6 8% for R-ORs and 77% 6 10% and 100% for ERs, respec-
tively, (P ¼ not signiﬁcant). Freedom from symptom recurrence and reinter-
ventions at 1 year was 88% 6 6% and 87% 6 7% for R-ORs and 83% 6 8%
and 71% 6 10% for ERs. Using propensity score matched comparison,
R-ORs were associated with similar mortality, morbidity, patency, recur-
rence, and reintervention rates compared with ﬁrst-time ORs.
Conclusions: Reinterventions for failing open mesenteric reconstruc-
tions using R-OR or ER interventions carry similar mortality, patency, recur-
rence, and reintervention rates. Early morbidity is signiﬁcantly lower with
endovascular compared with R-ORs performed for CMI. Outcomes of R-
ORs are similar to those obtainedwith the ﬁrst timeORs in patientswithCMI.
Multicenter Experience With Retrograde Open Mesenteric Artery
Stenting via Laparotomy for Treatment of Acute and Chronic
Mesenteric Ischemia
Rodrigo Almeida Coelho Macedo, MD1, Gustavo S. Oderich, MD1, Kalra
Manju, MD1, David Stone, MD2, Edward Woo, MD3, Jean
Panneton, MD4, Timothy Resch, MD5, Marc Schermerhorn, MD6, Jason
Lee, MD7, John Fallon, MD2, Tareq Massimi, MD4, Ben Herdrich, MD3,
Tommy Curran, MD6, Peter Gloviczki, MD1, Audra Duncan, MD1, Mark
Fleming, MD1, Randall De Martino, MD1, Thomas Bower, MD1. 1Mayo
Clinic, Rochester, Minn; 2Dartmouth-Hitchcock Medical Center, Lebanon,
NH; 3University of Pennsylvania, Philadelphia, Pa; 4Eastern Virginia Medical
School, Norfolk, Va; 5Skane University Hospital, Malmo, Sweden; 6Beth
Israel Deaconess Medical Center, Boston, Mass; 7Stanford University,
Stanford, Calif
Objectives: Retrograde open mesenteric stenting (ROMS) via lapa-
rotomy was introduced as an alternative to surgical bypass in patients with
acute mesenteric ischemia (AMI). The purpose of this study was to evaluate
the indications and outcomes of ROMS for treatment of acute and chronic
mesenteric ischemia (CMI).
Methods: We reviewed the clinical data and outcomes of all consecu-
tive patients treated by ROMS in seven academic centers from 2001 to
2013. ROMS was performed via laparotomy with retrograde access into
the target mesenteric artery and stent placement using a retrograde or ante-
grade approach, or both. End points were early and late (>30 days) mortal-
ity, morbidity, patient survival, patency rates, and freedom from symptom
recurrence and reintervention.
Results: There were 54 patients, 13 male and 41 female, with mean
age of 71 6 11 years. Indications for ROMS were AMI in 44 patients
(81%) and CMI with ﬂush mesenteric occlusions in 10 (19%). Four celiac
axis lesions and 53 superior mesenteric artery lesions were treated by stent-
ing. The mean stent length was 42 6 25 mm. Retrograde mesenteric access
was used in all patients, but 16 required a simultaneous antegrade approach.
The retrograde puncture was closed primarily in 35 patients or with patch
angioplasty in 17 and manual compression in one. Bowel resection was
needed in 29 patients (54%) with AMI because of perforation or gangrene.
Technical success was 98%. One patient was treated by bypass because an
attempted ROMS failed. Early mortality was 41% (18 of 44) for AMI and
10% (1 of 10) for CMI (P < .01). Early morbidity was 73% for AMI and
50% for CMI (P < .01). Mean follow-up was 11 6 19 months. Patient sur-
vival at 1 year was 36% 6 11% for AMI and 68% 6 12% for CMI (P ¼ .29).
For the entire cohort, primary and secondary patency was 65% 6 11% and
